Arch Therapeutics (ARTH) 10-K 11 Dec 15 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2015	Dec. 10, 2015	Mar. 31, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Fiscal Year Focus	2,015
Entity Registrant Name	Arch Therapeutics, Inc.
Entity Central Index Key	1,537,561
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Trading Symbol	ARTH
Document Period End Date	Sep. 30, 2015
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 10,000,000
Entity Common Stock, Shares Outstanding		108,879,552

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Current assets:
Cash	$ 3,960,100	$ 833,520
Prepaid expenses and other current assets	42,919	43,470
Total current assets	4,003,019	876,990
Long-term assets:
Total assets	4,003,019	876,990
Current liabilities:
Accounts payable	231,761	175,832
Accrued expenses and other liabilities	245,478	267,835
Convertible notes, net of unamortized discount	473,747	0
Current derivative liabilities	335,092	2,280,000
Total current liabilities	1,286,078	2,723,667
Long-term liabilities:
Note payable, net of unamortized discount	966,824	955,766
Accrued interest, net of current portion	210,000	100,000
Derivative liabilities, net of current portion	0	3,990,000
Total long-term liabilities	1,176,824	5,045,766
Total liabilities	$ 2,462,902	$ 7,769,433
Commitments and contingencies (see Note 12)
Stockholders’ equity (deficit):
Common stock, $0.001 par value, 300,000,000 shares authorized, 107,542,205 and 72,076,487 shares issued and outstanding as of September 30, 2015 and September 30, 2014, respectively	$ 107,392	$ 72,051
Additional paid in capital	17,154,945	5,810,200
Accumulated deficit	(15,722,220)	(12,774,694)
Total stockholders’ equity (deficit)	1,540,117	(6,892,443)
Total liabilities and stockholders' equity (deficit)	$ 4,003,019	$ 876,990

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Sep. 30, 2014
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares Issued	107,542,205	72,076,487
Common Stock, Shares Outstanding	107,542,205	72,076,487

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Revenues	$ 0	$ 0
Operating expenses:
General and administrative expenses	3,700,477	3,134,285
Research and development expenses	1,760,037	1,477,479
Total operating expenses	5,460,514	4,611,764
Operating loss	(5,460,514)	(4,611,764)
Other income (expense):
Interest expense	(377,805)	(111,059)
Fair value of derivative liabilities in excess of proceeds	0	(7,541,693)
Gain on exercise of warrants and conversion of debt	386,612	0
Loss on warrant derivative modification, net of inducement shares	(1,032,113)	0
Decrease to fair value of derivative	3,536,294	4,121,693
Total other income (expense)	2,512,988	(3,531,059)
Net Loss	$ (2,947,526)	$ (8,142,823)
Earnings per share - basic and diluted
Net loss per common share - basic and diluted	$ (0.04)	$ (0.12)
Weighted common shares - basic and diluted	81,394,873	67,492,823

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance at Sep. 30, 2013	$ 187,016	$ 60,145	$ 4,758,742	$ (4,631,871)
Beginning balance (in shares) at Sep. 30, 2013		60,145,237
Net loss	(8,142,823)	$ 0	0	(8,142,823)
Issuance of restricted stock for services	94,875	$ 275	94,600	0
Issuance of restricted stock for services (in shares)		275,000
Shares issued for the exercise of stock options	92,500	$ 231	92,269	0
Shares issued for the exercise of stock options (in shares)		231,250
Issuance of stock in Private Placement Funding	(225,297)	$ 11,400	(236,697)	0
Issuance of stock in Private Placement Funding (in shares)		11,400,000
Stock based compensation expense	1,101,286	$ 0	1,101,286	0
Ending balance at Sep. 30, 2014	(6,892,443)	$ 72,051	5,810,200	(12,774,694)
Ending balance (in shares) at Sep. 30, 2014		72,051,487
Net loss	(1,227,206)
Ending balance at Jun. 30, 2015	279,406
Beginning balance at Sep. 30, 2014	(6,892,443)	$ 72,051	5,810,200	(12,774,694)
Beginning balance (in shares) at Sep. 30, 2014		72,051,487
Net loss	(2,947,526)	$ 0	0	(2,947,526)
Issuance of restricted stock for services	166,157	$ 475	165,682	0
Issuance of restricted stock for services (in shares)		475,000
Reclassification of Series A and C Warrants	3,263,753	$ 0	3,263,753
Shares issued for the exercise of warrants	3,600,000	$ 18,687	3,581,313	0
Shares issued for the exercise of warrants (in shares)		18,686,801
Shares issued for the exercise of stock options	$ 0	$ 462	(462)	0
Shares issued for the exercise of stock options (in shares)	(1,025,000)	462,298
Shares issued in consideration for extending the Series C Warrants and eliminating the Ratchet Provision	$ 135,352	$ 570	134,782	0
Shares issued in consideration for extending the Series C Warrants and eliminating the Ratchet Provision (in shares)		570,000
Issuance of stock in Private Placement Funding	3,015,966	$ 14,391	3,001,575	0
Issuance of stock in Private Placement Funding (in shares)		14,390,754
Shares issued for the conversion of the convertible notes	151,173	$ 756	150,417	0
Shares issued for the conversion of the convertible notes (in shares)		755,865
Stock based compensation expense	1,047,685	$ 0	1,047,685	0
Ending balance at Sep. 30, 2015	$ 1,540,117	$ 107,392	$ 17,154,945	$ (15,722,220)
Ending balance (in shares) at Sep. 30, 2015		107,392,205

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net Loss	$ (2,947,526)	$ (8,142,823)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation Expense	0	322
Stock-based compensation	1,047,685	1,101,286
Noncash interest expense on notes payable	377,805	111,059
Issuance of restricted stock for services	166,157	94,875
Gain on exercise of warrants and conversion of debt	(386,612)	0
Loss on warrant derivative modification, net of inducement shares	1,032,113	0
Decrease to fair value of derivative	(3,536,294)	(4,121,693)
Fair value of derivative liabilities in excess of proceeds	0	7,541,693
Issuance of common stock for services	0	92,500
(Increase) decrease in:
Prepaid expenses and other current assets	551	(13,779)
Increase (decrease) in:
Accounts payable	55,929	(138,937)
Accrued expenses and other liabilities	(49,194)	126,995
Net cash used in operating activities	(4,239,386)	(3,348,502)
Cash flows from financing activities:
Proceeds from exercise of warrants	3,600,000	0
Proceeds from issuance of common stock and warrants	3,015,966	2,624,703
Proceeds from issuance of convertible notes	750,000	0
Proceeds from issuance of notes payable	0	1,000,000
Net cash provided by financing activities	7,365,966	3,624,703
Net increase in cash and cash equivalents	3,126,580	276,201
Cash and cash equivalents, beginning of period	833,520	557,319
Cash and cash equivalents, end of period	3,960,100	833,520
Non-cash financing activities
Issuance of Inducement shares	135,352	0
Conversion of 8% convertible notes and accrued interest to common stock	151,173	0
Reclassification of Series A and C Warrants from derivative liabilities to equity	3,263,753	0
Conversion feature embedded in convertible note	$ 354,988	$ 0

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS Arch Therapeutics, Inc., (together with its subsidiary, the “Company”) was incorporated under the laws of the State of Nevada on September 16, 2009, under the name “Almah, Inc.” to pursue the business of distributing automobile spare parts online. Effective June 26, 2013, the Company completed a merger (the “Merger”) with Arch Biosurgery, Inc. (formerly known as Arch Therapeutics, Inc.), a Massachusetts corporation (“ABS”), and Arch Acquisition Corporation (“Merger Sub”), the Company’s wholly owned subsidiary formed for the purpose of the transaction, pursuant to which Merger Sub merged with and into ABS and ABS thereby became the wholly owned subsidiary of the Company. As a result of the acquisition of ABS, the Company abandoned its prior business plan and has changed its operations to the business of a life science medical device company. Our current principal offices are located in Framingham, Massachusetts. For financial reporting purposes, the Merger represented a “reverse merger”. ABS was deemed to be the accounting acquirer in the transaction and the predecessor of Arch. Consequently, the accumulated deficit and the historical operations that are reflected in the Company’s consolidated financial statements prior to the Merger are those of ABS. All share information has been restated to reflect the effects of the Merger. The Company’s financial information has been consolidated with that of ABS after consummation of the Merger on June 26, 2013, and the historical financial statements of the Company before the Merger have been replaced with the historical financial statements of ABS before the Merger in this report. ABS was incorporated under the laws of Commonwealth of Massachusetts on March 6, 2006 as Clear Nano Solutions, Inc. On April 7, 2008, ABS changed its name from Clear Nano Solutions, Inc. to Arch Therapeutics, Inc. Effective upon the closing of the Merger, ABS changed its name from Arch Therapeutics, Inc. to Arch Biosurgery, Inc. The Company has generated no operating revenues to date, and is devoting substantially all of its efforts toward product research and development. To date, the Company has principally raised capital through borrowings and the issuance of convertible debt and units consisting of common stock and warrants. The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential products. The Company will be required to raise additional capital, obtain alternative means of financial support, or both, prior to or during May 2016 in order to continue to fund operations. However, there can be no assurance that the Company will be successful in securing additional resources when needed, on terms acceptable to the Company, if at all. Therefore, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary despite this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a life science medical device company. All intercompany accounts and transactions have been eliminated in consolidation. Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash. Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable in accordance with ASC 360, Property, Plant and Equipment The Company records a discount to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized to noncash interest expense using the effective interest rate method over the term of the related debt to their date of maturity. If a security or instrument becomes convertible only upon the occurrence of a future event outside the control of the Company, or, is convertible from inception, but contains conversion terms that change upon the occurrence of a future event, then any contingent beneficial conversion feature is measured and recognized when the triggering event occurs and contingency has been resolved. In accordance with ASC 740, Income Taxes The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is probable that a loss will be incurred related to these matters and the amount of the loss is reasonably determinable. The Company has no reserves related to uncertain tax positions as of September 30, 2015 and 2014. The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. The Company accounts for employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation Equity , In accordance with FASB ASC Topic 718, the Company has elected to use the Black-Scholes option pricing model to determine the fair value of options granted and recognizes the compensation cost of share-based awards on a straight-line basis over the vesting period of the award. The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company does not have a history of market prices of the common stock, and as such volatility is estimated in accordance with ASC 718-10-S99 Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures The Company’s financial instruments include cash and notes payable. Because of their short maturity, the carrying amount of cash and notes payable are considered to approximate fair value. The Company evaluated all events or transactions that occurred through December 10, 2015 the date which these consolidated financial statements were available to be issued. The Company disclosed material subsequent events in Note 15. The Company does not currently believe its existing cash resources are sufficient to meet its anticipated needs during the next twelve months. As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant recurring net losses and negative cash flows from operations, and has limited working capital. In addition, the Company does not have sufficient cash and cash equivalents to support its current operating plan. The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations. As of September 30, 2015, there is substantial doubt about our ability to continue as a going concern. The Company expects to incur substantial expenses for the foreseeable future for the research, development and commercialization of its potential products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may seek to acquire. Historically, the Company has funded its operations primarily through equity and debt financings. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments that might result from this uncertainty. The Company has determined that there had been an immaterial error in its accounting for the Series A Warrants, Series C Warrants, and Series D Warrants contained in its consolidated financial statements for the three and nine months ended June 30, 2015 filed with the Securities Exchange Commission on August 7, 2015. The Company determined that the Series A Warrants, Series C Warrants and Series D Warrants should have been presented in stockholders’ equity instead of as a liability. The Company assessed the materiality of this error in accordance with Staff Accounting Bulletin No. 99, Materiality

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	3. PROPERTY AND EQUIPMENT Estimated Useful Life 2015 2014 Furniture and fixtures 5 years $ 2,925 $ 2,925 Lab equipment 5 years 1,000 1,000 3,925 3,925 Less - accumulated depreciation 3,925 3,925 $ - $ -

INCOME TAXES

INCOME TAXES	12 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	4. INCOME TAXES 2015 2014 Net operating loss carryforwards $ 3,748,426 $ 2,731,492 Capitalized expenditures 802,769 381,872 Research and experimentation credit carryforwards 164,252 63,368 Stock based compensation 1,014,654 501,175 Property and Equipment 1,569 1,568 Accrued expenses 124,716 46,230 Gross deferred tax assets 5,856,386 3,725,705 Deferred tax asset valuation allowance (5,856,386) (3,725,705) Net deferred tax assets $ - $ - As of September 30, 2015 and 2014, the Company had federal net operating loss carryforwards of approximately $ 9,509,000 6,230,000 139,744 44,112 As of September 30, 2015 and 2014, the Company had state net operating loss carryforwards of approximately $ 8,487,000 5,271,000 37,000 19,000 As the Company has not yet achieved profitable operations, management believes the tax benefits as of September 30, 2015 and 2014 did not satisfy the realization criteria set forth in FASB ASC Topic 740, Income Taxes, and therefore has recorded a valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2015 and 2014 by approximately $ 2,130,000 2,202,000 The Company experienced an ownership change as a result of the Merger described in Note 6, causing a limitation on the annual use of the net operating loss carryforwards, which are subject to a substantial annual limitation due to the ownership change limitations set forth in Internal Revenue Code Section 382 and similar state provisions. As of September 30, 2015, the Company is open to examination in the U.S. federal and certain state jurisdictions for tax years ended September 30, 2015, 2014, 2013 and 2012.

PRIVATE PLACEMENT FINANCING 201

PRIVATE PLACEMENT FINANCING 2014	12 Months Ended
	Sep. 30, 2015
Private Placement Financing Two Thousand Fourteen [Member]
Private Placement [Line Items]
Private Placement Financing Disclosure [Text Block]	2014 PRIVATE PLACEMENT FINANCING On January 30, 2014, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with nine separate accredited investors (“2014 Investors”) providing for the issuance and sale by the Company to the 2014 Investors, in a private placement, of an aggregate of 11,400,000 0.25 34,200,000 2,850,000 Upon the closing of the 2014 Private Placement Financing on February 4, 2014 (the “Closing Date”), the Company entered into a registration rights agreement (the “2014 Registration Rights Agreement”) with the 2014 Investors, pursuant to which the Company became obligated, subject to certain conditions, to file with the Securities and Exchange Commission (“SEC”) on or before March 21, 2014 one or more registration statements to register for resale under the Securities Act of 1933, as amended, (i) the 2014 Shares and the 2014 Warrant Shares, plus (ii) an additional number of shares of common stock equal to 33% of the total number of 2014 Shares and 2014 Warrant Shares, to account for adjustments, if any, to the number of 2014 Warrant Shares issuable pursuant to the terms of the 2014 Warrants (the securities set forth in this clause (ii), the “Additional Shares”). Under the terms of the 2014 Registration Rights Agreement, the Company is permitted to reduce the number of shares covered by a registration statement if such reduction is required by the SEC as a condition for permitting such registration statement to become effective and treated as a resale registration statement (the “Cutback Provisions”). In response to comments received from the SEC and in accordance with the terms of the 2014 Registration Rights Agreement, the Company reduced the number of shares included in its draft resale registration statement by the number of Additional Shares. The Company’s failure to satisfy certain other obligations and deadlines set forth in the 2014 Registration Rights Agreement may subject the Company to payment of monetary penalties as discussed below, including liquidated damages. The resale registration statement was declared effective on July 2, 2014. The 2014 Warrants were exercisable immediately upon issuance. The Series A warrants had an initial exercise price of $ 0.30 0.35 12 0.40 18 4.9 The Company may be required to make certain payments to the 2014 Investors under certain circumstances in the future pursuant to the terms of the Securities Purchase Agreement and the 2014 Registration Rights Agreement. These potential future payments include: (a) potential partial damages for failure to register the common stock issued or issuable upon exercise of 2014 Warrants (in a cash amount equal to 1% of the price paid to the Company by each investor in the 2014 Private Placement Financing on the date of and on each 30-day anniversary of such failure until the cure thereof; (b) amounts payable if the Company and its transfer agent fail to timely remove certain restrictive legends from certificates representing shares of common stock issued in the 2014 Private Placement Financing or issuable upon exercise of the 2014 Warrants; (c) expense reimbursement for the lead investor in the 2014 Private Placement Financing; and (d) payments in respect of claims for which the Company provides indemnification. There is no cap to the potential consideration. On July 2, 2014, we received from the SEC a Notice of Effectiveness of our Registration Statement related to the 2014 Private Placement Financing which satisfied some of our obligation to register these securities with the SEC. On December 1, 2014, the Company agreed to amend certain provisions of the 2014 Warrants (the “December 2014 Amendment”). Under the terms of the December 2014 Amendment, the affected 2014 Warrants were amended to (i) reduce the exercise price of the Series B Warrants from $ 0.35 0.20 0.40 0.20 1,300,170 As of December 2, 2014, Series B Warrants had been exercised for an aggregate issuance of 4,000,000 800,000 224,000 On March 13, 2015, the Company issued unsecured 8% Convertible Notes, (the “Notes”), in the aggregate principal amount of $ 750,000 0.20 5,700,000 11,400,000 17,100,000 624,016 Prior to June 22, 2015, Series C Warrants had been exercised for an aggregate issuance of 2,255,000 451,000 75,321 During the year ended September 30, 2015, Series A Warrants, and Series C Warrants had been exercised for an aggregate issuance of 6,000,000 8,000,000 2,800,000 1,750,000 686,801 687 0.001 On June 22, 2015 the Company entered into the Amendment to the Series A Warrants and Series C Warrants to purchase Common Stock (the “June 2015 Amendment”), with Cranshire Capital Master Fund, Ltd. (“Cranshire”), to (i) delete the full ratchet anti-dilution provisions set forth in the Series A Warrants and Series C Warrants; and (ii) extend the expiration date of the Series C Warrants from 5:00 p.m., New York time, on July 2, 2015 to 5:00 p.m., New York time, on July 2, 2016. In consideration of Cranshire’s entrance into the June 2015 Amendment (and for no additional consideration), the Company agreed to issue to the holders of the 2014 Warrants up to 570,000 927,373 3,263,753 As of September 30, 2015, all 570,000 Derivative Liabilities The Company initially accounted for the 2014 Warrants relating to the aforementioned 2014 Private Placement Financing in accordance with ASC 815-10, Derivatives and Hedging On February 4, 2014, the closing date of the 2014 Private Placement Financing, the derivative liabilities were recorded at fair value of $ 10,391,693 2,850,000 7,541,693 The values of the derivative liability as of September 30, 2015 and 2014 were $ 0 6,270,000 896,763 4,121,693 299,321 3,263,753 4,000,000 Fair Value Measurements Using Significant Unobservable Warrant Derivative Liability 2015 2014 Beginning balance at September 30, $ 6,270,000 $ - Issuances - 10,391,693 Modification of warrants, net of Inducement Shares 896,763 - Exercises of warrants (299,321) - Adjustments to estimated fair value (3,603,689) (4,121,693) Reclass of Derivative Liability to Equity (3,263,753) - Ending balance at September 30, 2015 $ - $ 6,270,000 September 30, December 1, March 15, June 22, Closing price per share of Common Stock $ 0.18 $ 0.25 $ 0.21 $ 0.23 Exercise price per share $ 0.30 - 0.40 $ 0.20 - $0.30 $ 0.20 - $0.30 $ 0.20 Expected volatility 85 - 90 % 80 – 90 % 80 – 110 % 55- 85 % Risk-free interest rate 0.02 - 1.55 % .01 – 1.39 % 0.03 – 1.41 % 0.27 - 1.68 % Dividend yield — — — — Remaining expected term of underlying securities (years) 0.33 - 4.33 0.33 – 4.6 0.22 – 4.3 1.03 – 4.03 As of Exercises during th As of Closing price per share of Common Stock $ 0.26 $ 0.23-0.27 $ 0.27 Exercise price per share $ 0.20 $ 0.20 $ 0.20 Expected volatility 75-85 % 75- 85 % 75-85 % Risk-free interest rate 1.63 % 0.23-1.36 % 0.21-1.09 % Dividend yield — — — Remaining expected term of underlying securities (years) 1.01 0.80-3.96 0.76-3.76 Common Stock At the February 4, 2014 closing date of the 2014 Private Placement Financing, the Company issued 11,400,000 11,400 0.001

PRIVATE PLACEMENT FINANCING 212

PRIVATE PLACEMENT FINANCING 2015	12 Months Ended
	Sep. 30, 2015
Two Thousand Fifteen Private Placement Financing [Member]
Private Placement [Line Items]
Private Placement Financing Disclosure [Text Block]	6. 2015 PRIVATE PLACEMENT FINANCING Beginning June 22, 2015 and through June 30, 2015, the Company entered into a series of substantially similar subscription agreements (each a “Subscription Agreement”) with 20 accredited investors (collectively, the “2015 Investors”) providing for the issuance and sale by the Company to the 2015 Investors, in a private placement, of an aggregate of 14,390,754 0.22 0.25 3,200,000 The Company’s obligation to issue and sell the 2015 Shares and the Series D Warrants and the corresponding obligation of the 2015 Investors to purchase such 2015 Shares and Series D Warrants were subject to a number of conditions precedent including, but not limited to, the amendment of the Company’s Series A Warrants and Series C Warrants to delete certain of the anti-dilution provisions contained therein, as described in Footnote 5, Private Placement Financing, and other customary closing conditions. The conditions precedent were satisfied June 30, 2015 (the “Initial Closing Date”), and the Company conducted an initial closing (the “Initial Closing”) pursuant to which it sold and 19 of the 2015 Investors (the “Initial Investors”) purchased 13,936,367 3,066,000 454,387 100,000 On the Initial Closing Date, the Company entered into a registration rights agreement with the Initial Investors (the “ 2015 Registration Rights Agreement”), pursuant to which the Company was obligated, subject to certain conditions, to file with the Securities and Exchange Commission within 90 days after the closing of the 2015 Private Placement Financing one or more registration statements (any such registration statement, a “Resale Registration Statement”) to register the 2015 Shares and the 2015 Warrant Shares for resale under the Securities Act of 1933, as amended (the “Securities Act”). The remaining 2015 Investor became a party to the 2015 Registration Rights Agreement upon the consummation of the Second Closing. The Company’s failure to satisfy certain filing and effectiveness deadlines with respect to a Resale Registration Statement and certain other requirements set forth in the 2015 Registration Rights Agreement may subject the Company to payment of monetary penalties. On October 27, 2015, we received from the SEC a Notice of Effectiveness of our Registration Statement related to the 2015 Private Placement Financing which satisfied some of our obligation to register these securities with the SEC. Following each Closing, each 2015 Investor was also issued Series D Warrants to purchase shares of the Company’s Common Stock up to 100% of the 2015 Shares purchased by such 2015 Investor under such 2015 Investor’s Subscription Agreement. The Series D Warrants have an exercise price of $ 0.25 Common Stock At the June 30, 2015 Initial Closing Date of the 2015 Private Placement Financing, the Company issued 13,936,367 13,936 0.001 3,052,064 454,387 454 0.001 99,511

8% CONVERTIBLE NOTES

8% CONVERTIBLE NOTES	12 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
8% CONVERTIBLE NOTES	7. 8% CONVERTIBLE NOTES Beginning March 11, 2015 and through March 13, 2015, the Company entered into a series of substantially similar subscription agreements (each a “Subscription Agreement”) with each of Anson Investments Master Fund, Ltd., Equitec Specialists, LLC and Capital Ventures International (collectively, the “Note Investors”) pursuant to which the Company issued unsecured 8 750,000 250,000 The Notes become due and payable on March 13, 2016 (the “Stated Maturity Date”) and may not be prepaid. The Notes bear interest on the unpaid principal balance at a rate equal to eight percent ( 8.0 either (a) converted into shares of the Company’s common stock, $0.001 par value per share (“Common Stock”) or (b) the outstanding principal and accrued interest on the Notes is paid in full by the Company. Interest on the Notes becomes due and payable upon their conversion or the Stated Maturity Date and may become due and payable upon the occurrence of an event of default under the Notes. The Notes contain customary events of default, which include, among other things, (i) the Company’s failure to pay other indebtedness of $100,000 or more within the specified cure period for such breach; (iii) the acceleration of the stated maturity of such indebtedness; (iii) the insolvency of the Company; and (iv) the receipt of final, non-appealable judgments in the aggregate amount of $100,000 or more. On September 8, 2015, we, along with the current holders of the Convertible Notes, entered into a series of substantially similar subordination agreements with the Massachusetts Life Sciences Center (“ MLSC Subordination Agreements At any time prior to the Stated Maturity Date, the holders of the Notes have the right to convert some or all of such Notes into the number of shares of Common Stock determined by dividing (a) the aggregate sum of the (i) principal amount of the Note to be converted, and (ii) amount of any accrued but unpaid interest with respect to such portion of the Note to be converted; and (b) the conversion price then in effect (the shares of Common Stock issuable upon such conversion, the “Conversion Shares”). The initial conversion price is $ 0.20 4.99 9.99 145,000 6,173 755,865 The issuance and sale of the Notes and Conversion Shares (collectively, the “Securities”) has not been, and will not upon issuance be, registered under the Securities Act of 1933, as amended (the “Securities Act”), and the Securities may not be offered or sold in the United States absent registration under or exemption from the Securities Act and any applicable state securities laws. The Securities were issued and sold in reliance upon an exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act. Derivative Liabilities The Company accounted for the conversion feature embedded within the Notes in accordance with ASC 815-10, Derivatives and Hedging On the closing date, the derivative liability was recorded at fair value of $ 354,988 395,012 223,735 145,000 725,000 473,747 The value of the derivative liability as of September 30, 2015 was $ 335,092 67,395 87,291 Fair Value Measurements Using Significant Unobservable Convertible Beginning balance at September 30, 2014 $ - Issuances 354,988 Conversion of Notes (87,291) Adjustments to estimated fair value 67,395 Ending balance at September 30, 2015 $ 335,092 March 15, September 20, September 30, Stated interest rate 8.0 % 8.0 % 8.0 % Exercise price per share $ 0.20 $ 0.20 $ 0.20 Expected volatility 90.0 % 80.0 % 80.0 % Risk-free interest rate 0.24 % 0.09 % 0.07 % Credit adjusted discount rate 20.0 % 22.0 % 22.0 % Remaining expected term of underlying securities (years) 1.00 .48 .46

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	8. STOCK-BASED COMPENSATION 2013 Stock Incentive Plan On June 18, 2013, the Company established the 2013 Stock Incentive Plan (the “2013 Plan”). Under the 2013 Plan, during the fiscal year ended September 30, 2015, a maximum number of 13,114,256 3,000,000 3,000,000 16,114,256 As of September 30, 2015, a total of 8,479,212 4,652,500 Share-based awards During the year ended September 30, 2015, the Company granted options to employees and directors to purchase 3,175,000 1,087,500 1 10 3 0.17 0.28 The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period, with the exception of options granted subject to a consulting agreement, whereby the option vesting period and the service period are defined pursuant to the terms of the consulting agreement. Share-based compensation expense for awards granted during the year ended September 30, 2015 was based on the fair market value at period end or grant date fair value estimated using the Black-Scholes Option Pricing Model. The following assumptions were used to calculate the fair value of share based compensation for the year ended September 30, 2015; expected volatility, 76.6 119.4 0.64 2.03 0.00 0.00 1 10 Expected price volatility is the measure by which the Company’s stock price is expected to fluctuate during the expected term of an option. The Company exited shell company status on June 26, 2013. In situations where a newly public entity has limited historical data on the price of its publicly traded shares and no other traded financial instruments, authoritative guidance is provided on estimating this assumption by basing its expected volatility on the historical, expected, or implied volatility of similar entities whose share option prices are publicly available. In making the determination as to similarity, the guidance recommends the consideration of industry, stage of life cycle, size and financial leverage of such other entities. The Company’s expected volatility is derived from the historical daily change in the market price of its common stock since it exited shell company status, as well as the historical daily change in the market price for the peer group as determined by the Company. For so called “plain vanilla” options granted to employees, the expected term of the options is based upon the simplified method as defined in ASC 718-10-S99 which averages an award’s weighted-average vesting period and the contractual term for share options. The Company will continue to use the simplified method until it has the historical data necessary to provide a reasonable estimate of expected life in accordance with ASC Topic 718. The Company’s estimation of the expected term for stock options not subject to the simplified method is based upon the contractual term of the option award. For the purposes of estimating the fair value of stock option awards, the risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield. The Company has never paid any dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Stock-based compensation expense recognized in the Company’s consolidated statements of operations is based on awards ultimately expected to vest, reduced for estimated forfeitures. Authoritative guidance requires forfeitures to be estimated at the time of grant, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Prior to the year ended September 30, 2015, the Company did not experience any forfeitures of stock options. During the year ended September 30, 2015, the Company experienced an insignificant number of forfeitures of stock options granted. Since the Company has a limited history of stock option forfeitures it continues to estimate the forfeiture rate of its outstanding stock options as zero, but will continually evaluate its historical data as a basis for determining expected forfeitures. Common Stock Options Option Weighted Weighted Aggregate Outstanding at September 30, 2014 8,637,962 $ 0.38 - $ - Awarded 4,262,500 $ 0.21 - - Exercised 1,025,000 $ 0.33 - - Forfeited (1,098,962) $ 0.36 - - Outstanding at September 30, 2015 10,776,500 $ 0.30 6.85 $ 335,435 Vested 8,796,959 $ 0.32 4.73 $ 200,668 Vested and expected to vest at September 30, 2015 10,776,500 $ 0.30 6.85 $ 335,435 As of September 30, 2015, 781,506 1,048,000 1,101,000 466,000 629,000 582,000 472,000 As of September 30, 2015, there is approximately $ 607,000 1.62 Restricted Stock 2015 2014 Restricted Stock Non Vested at October 1 25,000 - Awarded - 300,000 Vested (25,000) (275,000) Forfeited - - Non Vested at September 30 - 25,000 2015 2014 Non Vested at October 1 $ 0.345 $ - Awarded - 0.345 Vested 0.345 0.345 Forfeited - - Non Vested at September 30 $ - $ 0.345 Non-employee restricted shares subject to vesting are revalued at each vesting date and at the end of the reporting period, with all changes in fair value recorded as stock-based compensation expense. For the year ended September 30, 2015 and 2014, compensation expense recorded for the restricted stock awards was approximately $ 9,000 95,000

2015 RESTRICTED STOCK

2015 RESTRICTED STOCK	12 Months Ended
	Sep. 30, 2015
Restricted Stock [Abstract]
2015 RESTRICTED STOCK	9. 2015 Restricted Stock On August 6, 2015, we entered into separate consulting agreements with two investor relations firms, Excelsior Global Advisors LLC (“ Excelsior Acorn 300,000 0.35 150,000 150,000 75,000 50,000 25,000 2015 Restricted Stock Non Vested at October 1 - Awarded 600,000 Vested (450,000) Forfeited - Non Vested at September 30 150,000 2015 Non Vested at October 1 $ - Awarded 0.35 Vested 0.35 Forfeited - Non Vested at September 30 $ 0.35 For the year ended September 30, 2015, compensation expense recorded for the restricted stock awards was approximately $ 157,000

COLDSTREAM FINANCING

COLDSTREAM FINANCING	12 Months Ended
	Sep. 30, 2015
Coldstream Financing [Abstract]
COLDSTREAM FINANCING	10. Coldstream Financing In contemplation of the Merger, (the “Merger”), on April 19, 2013, the Company entered into a financing agreement (the “Financing Agreement”) with Coldstream Summit Ltd. (“Coldstream”) pursuant to which we agreed to issue and sell, and Coldstream agreed to purchase or assist in securing the purchase of $ 2,000,000 0.50 0.75 4,000,000 4,000,000 2,000,000

NOTE PAYABLE

NOTE PAYABLE	12 Months Ended
	Sep. 30, 2015
Notes Payable [Abstract]
NOTE PAYABLE	11. Note Payable On September 30, 2013, the Company entered into the Life Sciences Accelerator Funding Agreement (the “MLSC Loan Agreement”) with the Massachusetts Life Sciences Center (“MLSC”), pursuant to which MLSC provided an unsecured subordinated loan in the amount of $ 1,000,000 The loan bears interest at a rate of 10% per annum, and will become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction or one or more financing transactions in which we receive from third parties other than our then existing shareholders net proceeds of $5,000,000 or more in a 12-month period 145,985 0.27 Of the $1,000,000, the Company allocated $ 944,707 55,293 11,000 966,824 955,766

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	12. COMMITMENTS AND CONTINGENCIES In the ordinary course of business, the Company enters into various agreements containing standard indemnification provisions. The Company's indemnification obligations under such provisions are typically in effect from the date of execution of the applicable agreement through the end of the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. As of September 30, 2015 and 2014, no amounts have been accrued related to such indemnification provisions. From time to time, the Company may be exposed to litigation in connection with its operations. The Company’s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. MIT Licensing Agreement In December, 2007, the Company entered into a license agreement with MIT pursuant to which the Company acquired an exclusive world-wide license to develop and commercialize technology related to self-assembling peptide compositions, and methods of making and using such compositions in medical and non-medical applications, including claims that cover the Company’s proposed products and methods of use thereof. The license also provides non-exclusive rights to additional intellectual property in the fields that cover the Company’s proposed products and methods of use thereof, in order to provide freedom to operate. The license provides the Company a right to sublicense the exclusively licensed intellectual property. The Company has not sublicensed the exclusively licensed intellectual property to any party for any field. In exchange for the licenses granted in the agreement, the Company has paid MIT license maintenance fees and patent prosecution costs. The Company paid license maintenance fees of $ 45,000 35,000 50,000 45,000 Annual license maintenance obligations extend through the life of the patents. Year Ending 2016 $ 50,000 2017 50,000 2018 50,000 2019 50,000 $ 200,000 In addition, MIT is entitled to royalties on applicable future product sales, if any. The annual payments may be applied towards royalties payable to MIT for that year for product sales. The Company is obligated to indemnify MIT and related parties from losses arising from claims relating to the exercise of any rights granted to the Company under the license, with certain exceptions. The maximum potential amount of future payments the Company could be required to make under this provision is unlimited. The Company considers there to be a low performance risk as of September 30, 2015. The agreement expires upon the expiration or abandonment of all patents that are issued and licensed to the Company by MIT under such agreement. The Company expects that patents will be issued from presently pending U.S. and foreign patent applications. Any such patent will have a term of 20 Leases We do not own any real property. In October 2013, we entered into a one and one-half year operating sublease agreement pursuant to which we leased the office space of our relocated headquarters in Wellesley, Massachusetts for a base annual rent equal to $ 5,031 2,000

IMMATERIAL CORRECTIONS TO PRIOR

IMMATERIAL CORRECTIONS TO PRIOR PERIOD FINANCIAL STATEMENTS	12 Months Ended
	Sep. 30, 2015
Accounting Changes and Error Corrections [Abstract]
IMMATERIAL CORRECTIONS TO PRIOR PERIOD FINANCIAL STATEMENTS	13. Immaterial Corrections to Prior Period Financial Statements The Company has determined that there had been an immaterial error in its accounting for the Series A Warrants, Series C Warrants, and Series D Warrants contained in its consolidated financial statements for the three and nine months ended June 30, 2015 filed with the Securities Exchange Commission on August 7, 2015. The Company determined that the Series A Warrants, Series C Warrants and Series D Warrants should have been presented in stockholders’ equity instead of as a liability. The Company assessed the materiality of this error in accordance with Staff Accounting Bulletin No. 99, Materiality 5,721,957 6,344,817 622,860 Previously Increase Reported (Decrease) Restated $ $ $ Liabilities Derivative liabilities, net of current portion 6,344,817 (6,344,817) - Total long-term liabilities 7,491,377 (6,344,817) 1,146,560 Total liabilities 9,383,266 (6,344,817) 3,038,449 Stockholders’ deficit Additional paid-in capital 8,566,193 5,721,957 14,288,150 Accumulated deficit (14,624,760) (622,860) (14,001,900) Total stockholders’ deficit (6,065,411) 6,344,817 279,406 The following table sets forth the effects of the adjustments discussed above on the consolidated statement of operations for the three and nine months ended June 30, 2015 Three months ended Nine Months Ended Previously Increase Restated Previously Increase Restated $ $ $ $ $ $ (Increase)/decrease to fair value of derivative (925,384) (622,860) (302,524) 2,924,064 (622,860) 3,546,924 Total other income (expense) (57,016) (622,860) 565,844 2,013,925 (622,860) 2,636,785 Net (loss)/income (1,395,245) (622,860) (772,385) (1,850,066) (622,860) (1,227,206) The following table sets forth the effects of the adjustments discussed above on the consolidated statement of cash flow as at June 30, 2015 Previously Increase Restated $ $ $ Net (loss) (1,850,066) (622,860) (1,277,206) Decrease to fair value of derivative (2,924,064) 622,860 (3,546,924)

RECLASSIFICATION OF PRIOR YEAR

RECLASSIFICATION OF PRIOR YEAR PRESENTATION	12 Months Ended
	Sep. 30, 2015
Reclassification of Prior Year Presentation [Abstract]
RECLASSIFICATION OF PRIOR YEAR PRESENTATION	14. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Cash Flows for fiscal year ended September 30, 2014, to identify the non cash expense for the issuance of warrants of $ 7,541,693

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	15. SUBSEQUENT EVENTS During the period commencing October 1, 2015 and ending on December 10, 2015, an additional 255,000 12,470 1,337,347

SUMMARY OF SIGNIFICANT ACCOUN22

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting	Basis of Accounting The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a life science medical device company. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable in accordance with ASC 360, Property, Plant and Equipment
Convertible Debt	Convertible Debt The Company records a discount to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized to noncash interest expense using the effective interest rate method over the term of the related debt to their date of maturity. If a security or instrument becomes convertible only upon the occurrence of a future event outside the control of the Company, or, is convertible from inception, but contains conversion terms that change upon the occurrence of a future event, then any contingent beneficial conversion feature is measured and recognized when the triggering event occurs and contingency has been resolved.
Income Taxes	Income Taxes In accordance with ASC 740, Income Taxes The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is probable that a loss will be incurred related to these matters and the amount of the loss is reasonably determinable. The Company has no reserves related to uncertain tax positions as of September 30, 2015 and 2014.
Research and Development	Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred.
Accounting for Stock-Based Compensation	Accounting for Stock-Based Compensation The Company accounts for employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation Equity , In accordance with FASB ASC Topic 718, the Company has elected to use the Black-Scholes option pricing model to determine the fair value of options granted and recognizes the compensation cost of share-based awards on a straight-line basis over the vesting period of the award. The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company does not have a history of market prices of the common stock, and as such volatility is estimated in accordance with ASC 718-10-S99 Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment
Fair Value Measurements	Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures The Company’s financial instruments include cash and notes payable. Because of their short maturity, the carrying amount of cash and notes payable are considered to approximate fair value.
Subsequent Events	The Company evaluated all events or transactions that occurred through December 10, 2015 the date which these consolidated financial statements were available to be issued. The Company disclosed material subsequent events in Note 15.
Going Concern Basis of Accounting	The Company does not currently believe its existing cash resources are sufficient to meet its anticipated needs during the next twelve months. As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant recurring net losses and negative cash flows from operations, and has limited working capital. In addition, the Company does not have sufficient cash and cash equivalents to support its current operating plan. The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations. As of September 30, 2015, there is substantial doubt about our ability to continue as a going concern. The Company expects to incur substantial expenses for the foreseeable future for the research, development and commercialization of its potential products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may seek to acquire. Historically, the Company has funded its operations primarily through equity and debt financings. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments that might result from this uncertainty.
Correction of an Immaterial Error	The Company has determined that there had been an immaterial error in its accounting for the Series A Warrants, Series C Warrants, and Series D Warrants contained in its consolidated financial statements for the three and nine months ended June 30, 2015 filed with the Securities Exchange Commission on August 7, 2015. The Company determined that the Series A Warrants, Series C Warrants and Series D Warrants should have been presented in stockholders’ equity instead of as a liability. The Company assessed the materiality of this error in accordance with Staff Accounting Bulletin No. 99, Materiality

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	At September 30, 2015 and 2014, property and equipment consisted of: Estimated Useful Life 2015 2014 Furniture and fixtures 5 years $ 2,925 $ 2,925 Lab equipment 5 years 1,000 1,000 3,925 3,925 Less - accumulated depreciation 3,925 3,925 $ - $ -

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets and liabilities	The principal components of the Company's net deferred tax assets consisted of the following at September 30: 2015 2014 Net operating loss carryforwards $ 3,748,426 $ 2,731,492 Capitalized expenditures 802,769 381,872 Research and experimentation credit carryforwards 164,252 63,368 Stock based compensation 1,014,654 501,175 Property and Equipment 1,569 1,568 Accrued expenses 124,716 46,230 Gross deferred tax assets 5,856,386 3,725,705 Deferred tax asset valuation allowance (5,856,386) (3,725,705) Net deferred tax assets $ - $ -

2014 PRIVATE PLACEMENT FINANCIN

2014 PRIVATE PLACEMENT FINANCING (Tables) - Private Placement Financing [Member]	12 Months Ended
	Sep. 30, 2015
Private Placement [Line Items]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The change in the estimated fair value was primarily due to the reduction of the exercise prices of the 2014 Warrants, the exercise of 4,000,000 Fair Value Measurements Using Significant Unobservable Warrant Derivative Liability 2015 2014 Beginning balance at September 30, $ 6,270,000 $ - Issuances - 10,391,693 Modification of warrants, net of Inducement Shares 896,763 - Exercises of warrants (299,321) - Adjustments to estimated fair value (3,603,689) (4,121,693) Reclass of Derivative Liability to Equity (3,263,753) - Ending balance at September 30, 2015 $ - $ 6,270,000
Schedule Of Assumptions Used To Value Derivative Liability	The derivative liabilities were valued as of September 30, 2014, December 1, 2014, and March 15, 2015 using Monte Carlo Simulation. The derivative liabilities as of June 22, 2015, June 30, 2015, and September 30, 2015 as well as the exercises during 4th quarter of fiscal 2015 were valued using Black Scholes. September 30, December 1, March 15, June 22, Closing price per share of Common Stock $ 0.18 $ 0.25 $ 0.21 $ 0.23 Exercise price per share $ 0.30 - 0.40 $ 0.20 - $0.30 $ 0.20 - $0.30 $ 0.20 Expected volatility 85 - 90 % 80 – 90 % 80 – 110 % 55- 85 % Risk-free interest rate 0.02 - 1.55 % .01 – 1.39 % 0.03 – 1.41 % 0.27 - 1.68 % Dividend yield — — — — Remaining expected term of underlying securities (years) 0.33 - 4.33 0.33 – 4.6 0.22 – 4.3 1.03 – 4.03 As of Exercises during th As of Closing price per share of Common Stock $ 0.26 $ 0.23-0.27 $ 0.27 Exercise price per share $ 0.20 $ 0.20 $ 0.20 Expected volatility 75-85 % 75- 85 % 75-85 % Risk-free interest rate 1.63 % 0.23-1.36 % 0.21-1.09 % Dividend yield — — — Remaining expected term of underlying securities (years) 1.01 0.80-3.96 0.76-3.76

8% CONVERTIBLE NOTES (Tables)

8% CONVERTIBLE NOTES (Tables)	12 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Derivative Liabilities at Fair Value	As a result of a change in the estimated fair value of the derivative liability we recorded other expense of $ 67,395 87,291 Fair Value Measurements Using Significant Unobservable Convertible Beginning balance at September 30, 2014 $ - Issuances 354,988 Conversion of Notes (87,291) Adjustments to estimated fair value 67,395 Ending balance at September 30, 2015 $ 335,092
Schedule of Assumptions Used	The derivative liability was valued as of March 15, 2015, September 20, and September 30, 2015 using Monte Carlo Simulations with the following assumptions: March 15, September 20, September 30, Stated interest rate 8.0 % 8.0 % 8.0 % Exercise price per share $ 0.20 $ 0.20 $ 0.20 Expected volatility 90.0 % 80.0 % 80.0 % Risk-free interest rate 0.24 % 0.09 % 0.07 % Credit adjusted discount rate 20.0 % 22.0 % 22.0 % Remaining expected term of underlying securities (years) 1.00 .48 .46

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables) - 2013 Stock Incentive Plan	12 Months Ended
	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity	Stock compensation activity under the 2013 Plan for the year ended September 30, 2015 follows: Option Weighted Weighted Aggregate Outstanding at September 30, 2014 8,637,962 $ 0.38 - $ - Awarded 4,262,500 $ 0.21 - - Exercised 1,025,000 $ 0.33 - - Forfeited (1,098,962) $ 0.36 - - Outstanding at September 30, 2015 10,776,500 $ 0.30 6.85 $ 335,435 Vested 8,796,959 $ 0.32 4.73 $ 200,668 Vested and expected to vest at September 30, 2015 10,776,500 $ 0.30 6.85 $ 335,435
Nonvested Restricted Stock Shares Activity	Restricted stock activity under the 2013 Plan for the years ended September 30, 2015 and 2014 follows: 2015 2014 Restricted Stock Non Vested at October 1 25,000 - Awarded - 300,000 Vested (25,000) (275,000) Forfeited - - Non Vested at September 30 - 25,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	2015 2014 Non Vested at October 1 $ 0.345 $ - Awarded - 0.345 Vested 0.345 0.345 Forfeited - - Non Vested at September 30 $ - $ 0.345

2015 RESTRICTED STOCK (Tables)

2015 RESTRICTED STOCK (Tables) - 2015 Restricted Stock [Member]	12 Months Ended
	Sep. 30, 2015
Nonvested Restricted Stock Shares Activity [Table Text Block]	Restricted Stock activity for the year ended September 30, 2015 follows: 2015 Restricted Stock Non Vested at October 1 - Awarded 600,000 Vested (450,000) Forfeited - Non Vested at September 30 150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	The weighted average restricted stock award date fair value information for the years ended September 30, 2015 follows: 2015 Non Vested at October 1 $ - Awarded 0.35 Vested 0.35 Forfeited - Non Vested at September 30 $ 0.35

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Annual License Maintenance Fee Commitments	The following table reflects the Company’s annual license maintenance fee commitments: Year Ending 2016 $ 50,000 2017 50,000 2018 50,000 2019 50,000 $ 200,000

IMMATERIAL CORRECTIONS TO PRI30

IMMATERIAL CORRECTIONS TO PRIOR PERIOD FINANCIAL STATEMENTS (Tables)	12 Months Ended
	Sep. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The following table sets forth the effects of the adjustments discussed above on the consolidated balance sheet as at June 30, 2015. Previously Increase Reported (Decrease) Restated $ $ $ Liabilities Derivative liabilities, net of current portion 6,344,817 (6,344,817) - Total long-term liabilities 7,491,377 (6,344,817) 1,146,560 Total liabilities 9,383,266 (6,344,817) 3,038,449 Stockholders’ deficit Additional paid-in capital 8,566,193 5,721,957 14,288,150 Accumulated deficit (14,624,760) (622,860) (14,001,900) Total stockholders’ deficit (6,065,411) 6,344,817 279,406 The following table sets forth the effects of the adjustments discussed above on the consolidated statement of operations for the three and nine months ended June 30, 2015 Three months ended Nine Months Ended Previously Increase Restated Previously Increase Restated $ $ $ $ $ $ (Increase)/decrease to fair value of derivative (925,384) (622,860) (302,524) 2,924,064 (622,860) 3,546,924 Total other income (expense) (57,016) (622,860) 565,844 2,013,925 (622,860) 2,636,785 Net (loss)/income (1,395,245) (622,860) (772,385) (1,850,066) (622,860) (1,227,206) The following table sets forth the effects of the adjustments discussed above on the consolidated statement of cash flow as at June 30, 2015 Previously Increase Restated $ $ $ Net (loss) (1,850,066) (622,860) (1,277,206) Decrease to fair value of derivative (2,924,064) 622,860 (3,546,924)

Property and Equipment (Detail)

Property and Equipment (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Property, plant and equipment, gross, total	$ 3,925	$ 3,925
Less - accumulated depreciation	3,925	3,925
Property, plant and equipment, net, total	$ 0	0
Furniture and fixtures
Property, plant and equipment, useful life	5 years
Property, plant and equipment, gross, total	$ 2,925	2,925
Lab equipment
Property, plant and equipment, useful life	5 years
Property, plant and equipment, gross, total	$ 1,000	$ 1,000

Income Taxes (Detail)

Income Taxes (Detail) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Income Taxes [Line Items]
Net operating loss carryforwards	$ 3,748,426	$ 2,731,492
Capitalized expenditures	802,769	381,872
Research and experimentation credit carryforwards	164,252	63,368
Stock based compensation	1,014,654	501,175
Property and Equipment	1,569	1,568
Accrued expenses	124,716	46,230
Gross deferred tax assets	5,856,386	3,725,705
Deferred tax asset valuation allowance	(5,856,386)	(3,725,705)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Taxes [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 9,509,000	$ 6,230,000
Research and experimentation credit carryforwards	164,252	63,368
Deferred tax assets, operating loss carryforwards, state and local	8,487,000	5,271,000
Valuation allowance, deferred tax asset, change in amount	2,130,000	2,202,000
Expire In 2023
Income Taxes [Line Items]
Research and experimentation credit carryforwards	37,000	19,000
Expire in 2029
Income Taxes [Line Items]
Research and experimentation credit carryforwards	$ 139,744	$ 44,112

Fair Value Measurements Using S

Fair Value Measurements Using Significant Unobservable Inputs Level 3 (Detail) - USD ($)	Mar. 13, 2015	Sep. 30, 2015	Sep. 30, 2014
Modification of warrants, net of Inducement Shares	$ 624,016	$ 2,980,829
Exercises of Warrants		(386,612)	$ 0
Adjustments to estimated fair value		0	7,541,693
Fair Value, Inputs, Level 3 | Private Placement Financing [Member]
Balance		6,270,000	0
Issuances		0	10,391,693
Modification of warrants, net of Inducement Shares		896,763	0
Exercises of Warrants		(299,321)	0
Adjustments to estimated fair value		(3,603,689)	(4,121,693)
Reclass of Derivative Liability to Equity		(3,263,753)	0
Balance		$ 0	$ 6,270,000

Assumptions Used For Derivative

Assumptions Used For Derivative Liability (Detail) - $ / shares	Jun. 30, 2015	Mar. 15, 2015	Dec. 01, 2014	Sep. 30, 2015	Sep. 20, 2015	Jun. 22, 2015	Sep. 30, 2014	Sep. 30, 2015
Closing price per share of Common Stock				$ 0.001			$ 0.001	$ 0.001
Exercise price per share		$ 0.20		$ 0.20	$ 0.20			0.20
Expected volatility		90.00%		80.00%	80.00%
Risk-free interest rate		0.24%		0.07%	0.09%
Dividend yield		20.00%		22.00%	22.00%
Remaining expected term of underlying securities (years)		1 year		5 months 16 days	5 months 23 days
Derivative liabilities Assumptions | Private Placement Financing
Closing price per share of Common Stock	$ 0.26	$ 0.21	$ 0.25	$ 0.27		$ 0.23	$ 0.18	0.27
Exercise price per share	$ 0.20			$ 0.20				0.20
Risk-free interest rate	1.63%
Dividend yield	0.00%	0.00%	0.00%	0.00%		0.00%	0.00%
Remaining expected term of underlying securities (years)	1 year 4 days
Derivative liabilities Assumptions | Private Placement Financing | Exercises during 4th Quarter [Member]
Exercise price per share				$ 0.20				$ 0.20
Dividend yield								0.00%
Maximum | Derivative liabilities Assumptions | Private Placement Financing
Exercise price per share		$ 0.30	$ 0.30				$ 0.40
Expected volatility	85.00%	110.00%	90.00%	85.00%		85.00%	90.00%
Risk-free interest rate		1.41%	1.39%	1.09%		1.68%	1.55%
Remaining expected term of underlying securities (years)		4 years 3 months 18 days	4 years 7 months 6 days	3 years 9 months 4 days		4 years 11 days	4 years 3 months 29 days
Maximum | Derivative liabilities Assumptions | Private Placement Financing | Exercises during 4th Quarter [Member]
Closing price per share of Common Stock				$ 0.27				$ 0.27
Expected volatility								85.00%
Risk-free interest rate								1.36%
Remaining expected term of underlying securities (years)								3 years 11 months 16 days
Minimum | Derivative liabilities Assumptions | Private Placement Financing
Exercise price per share		$ 0.20	$ 0.20				$ 0.30
Expected volatility	75.00%	80.00%	80.00%	75.00%		55.00%	85.00%
Risk-free interest rate		0.03%	0.01%	0.21%		0.27%	0.02%
Remaining expected term of underlying securities (years)		2 months 19 days	3 months 29 days	9 months 4 days		1 year 11 days	3 months 29 days
Minimum | Derivative liabilities Assumptions | Private Placement Financing | Exercises during 4th Quarter [Member]
Closing price per share of Common Stock				$ 0.23				$ 0.23
Expected volatility								75.00%
Risk-free interest rate								0.23%
Remaining expected term of underlying securities (years)								9 months 18 days

2014 Private Placement Financ36

2014 Private Placement Financing - Additional Information (Detail) - USD ($)	Jul. 02, 2015	Jun. 30, 2015	Mar. 13, 2015	Dec. 02, 2014	Dec. 01, 2014	Jun. 22, 2015	Feb. 04, 2014	Jan. 30, 2014	Apr. 19, 2013	Jun. 30, 2015	Jun. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 20, 2015	Aug. 06, 2015	Mar. 15, 2015
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Stock issued during period, shares, new issues	454,387
Share price															$ 0.35
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.75
Common Stock												$ 107,392	$ 72,051
Common Stock, Shares Issued												107,542,205	72,076,487
Common Stock, Par or Stated Value Per Share												$ 0.001	$ 0.001
Derivative, Fair Value, Net, Total						$ 927,373
Exercises of Warrants									$ 2,000,000			$ 451,000
Fair Value Of Derivative Liabilities In Excess Of Proceeds												0	$ (7,541,693)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)										$ (302,524)	$ 3,546,924	$ 3,536,294	4,121,693
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period												(1,025,000)
Gain On Warrant Derivative Modification			$ 624,016									$ 2,980,829
Gain On Exercise Of Warrants												$ 386,612	0
Gains (Losses) on Extinguishment of Debt				$ 224,000
Debt Instrument, Interest Rate, Stated Percentage												8.00%		8.00%		8.00%
Stock Issued During Period Inducement Shares												$ 570,000
Reclassification of Series A and C Warrants from derivative liabilities to equity												$ 3,263,753	0
2014 Private Placement
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Stock issued during period, shares, new issues		14,390,754						11,400,000
Share price								$ 0.25				$ 0.22
Common Stock Issuance Upon Exercise Of Warrants								34,200,000
Proceeds from issuance of common stock		$ 3,200,000						$ 2,850,000
Common Stock							$ 11,400
Common Stock, Shares Issued							11,400,000
Common Stock, Par or Stated Value Per Share							$ 0.001					$ 0.001
Derivative, Fair Value, Net, Total							$ 10,391,693
Exercises of Warrants							2,850,000
Fair Value Of Derivative Liabilities In Excess Of Proceeds							$ 7,541,693					$ 3,052,064
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value												$ 0	$ 6,270,000
Derivative Liability						$ 3,263,753
Series A Warrants
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.30
Derivative, Fair Value, Net, Total												$ 6,000,000
Reduction In Exercise Price Of Warrants			$ 0.20
Additional Warrants Issued			5,700,000
Stock Issued During Period Shares Warrants Exercised												1,750,000
Series A Warrants | Minimum [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Class of Warrant or Right, Outstanding			11,400,000
Series A Warrants | Maximum [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Class of Warrant or Right, Outstanding			17,100,000
Series B Warrants
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Proceeds from issuance of common stock				$ 800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.35
Exercise Term Of Warrants												12 months
Common Stock, Shares Issued				4,000,000
Derivative, Fair Value, Net, Total												$ 2,255,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period												4,000,000
Gain On Warrant Derivative Modification					$ 1,300,170
Series B Warrants | Minimum [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.20
Series B Warrants | Maximum [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					0.35
Series C Warrants
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.40
Percentage Of Exercisability Of Warrants												4.90%
Exercise Term Of Warrants												18 months
Derivative, Fair Value, Net, Total												$ 8,000,000
Series C Warrants | Minimum [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					0.20
Series C Warrants | Maximum [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.40
2014 Warrant
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Debt Instrument, Face Amount			$ 750,000
Adjustments to Additional Paid in Capital, Warrant Issued												55,293
2014 Warrant | 2014 Private Placement
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Stock issued during period, shares, new issues						570,000
Series A And Series C Warrants [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Exercises of Warrants												$ 2,800,000
Common Stock [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period												462,298	231,250
Stock Issued During Period Shares Warrants Exercised												18,686,801
Stock Issued During Period, Shares, Other												686,801
Adjustments to Additional Paid in Capital, Warrant Issued												$ 687

Private Placement Financing (20

Private Placement Financing (2015) - Additional Information (Detail) - USD ($)	Jul. 02, 2015	Jul. 02, 2015	Jun. 30, 2015	Jun. 30, 2015	Feb. 04, 2014	Jan. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Aug. 06, 2015	Apr. 19, 2013
Private Placement [Line Items]
Stock Issued During Period, Shares, New Issues		454,387
Share Price									$ 0.35
Common Stock, Par or Stated Value Per Share							$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.75
Fair Value Of Derivative Liabilities In Excess Of Proceeds							$ 0	$ (7,541,693)
2014 Investor
Private Placement [Line Items]
Stock Issued During Period, Shares, New Issues		454,387
Proceeds from Issuance of Common Stock		$ 100,000
Series D Warrants
Private Placement [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.25
Series A And Series C Warrants [Member]
Private Placement [Line Items]
Stock Issued During Period, Shares, New Issues							13,936,367
Proceeds from Issuance of Common Stock							$ 3,066,000
2014 Private Placement
Private Placement [Line Items]
Stock Issued During Period, Shares, New Issues			14,390,754			11,400,000
Share Price						$ 0.25	$ 0.22
Common Stock, Par or Stated Value Per Share					$ 0.001		$ 0.001
Proceeds from Issuance of Common Stock			$ 3,200,000			$ 2,850,000
Fair Value Of Derivative Liabilities In Excess Of Proceeds					$ 7,541,693		$ 3,052,064
2014 Private Placement | Series D Warrants
Private Placement [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.25
2015 Private Placement [Member]
Private Placement [Line Items]
Stock Issued During Period, Shares, New Issues				13,936,367
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Fair Value Of Derivative Liabilities In Excess Of Proceeds	$ 99,511
Stock Issued During Period, Value, New Issues	$ 454			$ 13,936

Estimated fair market value of

Estimated fair market value of the derivative liability (Detail) - Convertible Debt [Member]	12 Months Ended
	Sep. 30, 2015USD ($)
Derivative [Line Items]
Conversion of Notes	$ (87,291)
Fair Value, Inputs, Level 3 [Member]
Derivative [Line Items]
Beginning balance at September 30, 2014	0
Issuances	354,988
Conversion of Notes	(87,291)
Adjustments to estimated fair value	67,395
Ending balance at September 30, 2015	$ 335,092

Derivative liability for Monte

Derivative liability for Monte Carlo Simulations (Detail) - $ / shares	Mar. 15, 2015	Sep. 30, 2015	Sep. 20, 2015
Derivative [Line Items]
Stated interest rate	8.00%	8.00%	8.00%
Exercise price per share	$ 0.20	$ 0.20	$ 0.20
Expected volatility	90.00%	80.00%	80.00%
Risk-free interest rate	0.24%	0.07%	0.09%
Credit adjusted discount rate	20.00%	22.00%	22.00%
Remaining expected term of underlying securities (years)	1 year	5 months 16 days	5 months 23 days

8% Convertible Notes - Addition

8% Convertible Notes - Additional Information (Detail) - USD ($)	Mar. 15, 2015	Mar. 13, 2015	Sep. 30, 2015	Sep. 20, 2015	Sep. 30, 2014
8% Convertible Notes [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%		8.00%	8.00%
Debt Instrument, Convertible, Conversion Price		$ 0.20
Interest Expense, Debt			$ 11,000
Convertible Notes Payable, Current			$ 473,747		$ 0
Common Stock [Member]
8% Convertible Notes [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities			755,865
Debt [Member]
8% Convertible Notes [Line Items]
Interest Expense, Debt			$ 223,735
Convertible Notes Payable, Current			$ 473,747
Maximum [Member]
8% Convertible Notes [Line Items]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		9.99%
Minimum [Member]
8% Convertible Notes [Line Items]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		4.99%
Subscription Agreement [Member]
8% Convertible Notes [Line Items]
Debt Instrument, Face Amount		$ 750,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%	8.00%
Debt Conversion, Description		either (a) converted into shares of the Companys common stock, $0.001 par value per share (Common Stock) or (b) the outstanding principal and accrued interest on the Notes is paid in full by the Company. Interest on the Notes becomes due and payable upon their conversion or the Stated Maturity Date and may become due and payable upon the occurrence of an event of default under the Notes. The Notes contain customary events of default, which include, among other things, (i) the Companys failure to pay other indebtedness of $100,000 or more within the specified cure period for such breach; (iii) the acceleration of the stated maturity of such indebtedness; (iii) the insolvency of the Company; and (iv) the receipt of final, non-appealable judgments in the aggregate amount of $100,000 or more.
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	$ 354,988		$ 335,092
Other Noncash Expense			67,395
Proceeds from Issuance of Debt	$ 395,012
Subscription Agreement [Member] | Investor [Member]
8% Convertible Notes [Line Items]
Debt Instrument, Face Amount		$ 250,000
Convertible Debt [Member]
8% Convertible Notes [Line Items]
Debt Instrument, Annual Principal Payment			145,000
Debt Instrument, Periodic Payment, Interest			$ 6,173
Stock Issued During Period, Shares, Conversion of Convertible Securities			725,000
Derivative, Gain on Derivative			$ 87,291

Stock Based Compensation Stock

Stock Based Compensation Stock Option Activity (Detail) - USD ($)	Aug. 06, 2015	Sep. 30, 2015
Option Shares Outstanding
Outstanding, Beginning Balance		8,637,962
Awarded		4,262,500
Exercised		1,025,000
Forfeited		(1,098,962)
Outstanding, Ending Balance		10,776,500
Vested	150,000	8,796,959
Vested and expected to vest		10,776,500
Weighted Average Exercise Price
Outstanding, Beginning Balance		$ 0.38
Awarded		0.21
Exercised		0.33
Forfeited		0.36
Outstanding, Ending Balance		0.3
Vested		0.32
Vested and expected to vest		$ 0.3
Weighted Average Remaining Contractual Term (years)
Awarded		0 years
Exercised		0 years
Forfeited		0 years
Balance		6 years 10 months 6 days
Vested		4 years 8 months 23 days
Vested and expected to vest		6 years 10 months 6 days
Aggregate Intrinsic Value
Outstanding, Beginning Balance		$ 0
Awarded		0
Exercised		0
Forfeited		0
Outstanding, Ending Balance		335,435
Vested		200,668
Vested and expected to vest		$ 335,435

Stock Based Compensation Restri

Stock Based Compensation Restricted Stock Award Activity (Detail) - Restricted Stock - shares	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Weighted Average Grant Date Fair Value
Non Vested, Beginning Balance	25,000	0
Awarded	0	300,000
Vested	(25,000)	(275,000)
Forfeited	0	0
Non Vested, Ending Balance	0	25,000

Weighted Average Restricted Sto

Weighted Average Restricted Stock Award (Detail) - $ / shares	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non Vested, Beginning Balance	$ 0.345	$ 0
Awarded	0	0.345
Vested	0.345	0.345
Forfeited	0	0
Non Vested, Ending Balance	$ 0	$ 0.345

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	Oct. 02, 2015	Sep. 30, 2015	Sep. 30, 2014	Jun. 18, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase In Aggregate Number Of Shares				3,000,000
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term		6 years 10 months 6 days
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 0.21
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum		76.60%
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum		119.40%
Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum		0.64%
Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum		2.03%
Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate		0.00%
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate		0.00%
Share-based compensation arrangement by share-based payment award, number of shares available for grant		781,506
Common Stock, Shares Authorized		300,000,000	300,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		4,262,500
Non-Employee Resricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense		$ 9,000	$ 95,000
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense		466,000	629,000
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense		$ 582,000	472,000
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 0.28
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected term		10 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 0.17
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected term		1 year
Employees And Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense		$ 1,048,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		8,479,212
Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense			$ 1,101,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		4,652,500
2013 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, total		$ 607,000
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition		1 year 7 months 13 days
Common Stock, Shares Authorized	16,114,256			13,114,256
Share-based compensation arrangement by share-based payment award, number of additional shares authorized	3,000,000
2013 Stock Incentive Plan | Employees And Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		3,175,000
2013 Stock Incentive Plan | Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,087,500
2013 Stock Incentive Plan | Consultants | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term		10 years
2013 Stock Incentive Plan | Consultants | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term		1 year

Restricted Stock activity (Deta

Restricted Stock activity (Detail) - 2015 Restricted Stock [Member]	12 Months Ended
	Sep. 30, 2015shares
Non Vested, Beginning Balance	0
Awarded	600,000
Vested	(450,000)
Forfeited	0
Non Vested, Ending Balance	150,000

Weighted average restricted s46

Weighted average restricted stock award (Detail 1) - $ / shares	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Non Vested, Beginning Balance	$ 0.345	$ 0
Awarded	0	0.345
Vested	0.345	0.345
Forfeited	0	0
Non Vested, Ending Balance	0	0.345
2015 Restricted Stock [Member]
Non Vested, Beginning Balance	0
Awarded	0.35
Vested	0.35
Forfeited	0
Non Vested, Ending Balance	$ 0.35	$ 0

2015 Restricted Stock - Additio

2015 Restricted Stock - Additional Information (Detail) - USD ($)	Aug. 06, 2015	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	300,000
Share Price	$ 0.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	150,000	8,796,959
Share-based Compensation, Total		$ 1,047,685	$ 1,101,286
Restricted Stock [Member]
Share-based Compensation, Total		$ 157,000
September 4, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	75,000
October 2, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	50,000
November 4, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	25,000
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	150,000

Coldstream Financing - Addition

Coldstream Financing - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 19, 2013	Sep. 30, 2015	Sep. 30, 2014
Coldstream Financing [Line Items]
Proceeds from issuance of private placement	$ 2,000,000	$ 451,000
Unit issued price per share.	$ 0.50
Class of warrant or right, exercise price of warrants or rights	$ 0.75
Proceeds from investors in contemplation of merger	$ 2,000,000
Common Stock, Shares Issued		107,542,205	72,076,487
Coldstream Financing
Coldstream Financing [Line Items]
Warrants issued to purchase of common stock	4,000,000
Common Stock, Shares Issued	4,000,000

Note Payable - Additional Infor

Note Payable - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2015	Sep. 30, 2014	Apr. 19, 2013
Note Payable [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.75
Interest Expense, Debt		$ 11,000
Debt instrument, unamortized discount		966,824	$ 955,766
Loans
Note Payable [Line Items]
Notes Payable		944,707
2014 Warrant
Note Payable [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued		$ 55,293
Massachusetts Life Sciences Center
Note Payable [Line Items]
Subordinated Debt	$ 1,000,000
Debt Instrument, Payment Terms	The loan bears interest at a rate of 10% per annum, and will become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction or one or more financing transactions in which we receive from third parties other than our then existing shareholders net proceeds of $5,000,000 or more in a 12-month period
Warrants Issued To Purchase Of Common Stock	145,985
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.27

Annual License Maintenance Fee

Annual License Maintenance Fee Commitments (Detail) - License Maintenance Obligation [Member]	Sep. 30, 2015USD ($)
Contractual Obligation Fiscal Year Maturity [Line Items]
2,016	$ 50,000
2,017	50,000
2,018	50,000
2,019	50,000
Contractual obligation, total	$ 200,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 30, 2015	Oct. 31, 2013	Sep. 30, 2015	Sep. 30, 2014
Commitments And Contingencies [Line Items]
License Maintenance Costs			$ 45,000	$ 35,000
Wellesley [Member]
Commitments And Contingencies [Line Items]
Payments For Rent Monthly Payments		$ 5,031
Framingham [Member]
Commitments And Contingencies [Line Items]
Payments For Rent Monthly Payments	$ 2,000
Patents
Commitments And Contingencies [Line Items]
Finite-Lived Intangible Asset, Useful Life			20 years
MIT Licensing Agreement
Commitments And Contingencies [Line Items]
Contractual Obligation			$ 50,000	$ 45,000

Immaterial Corrections to Pri52

Immaterial Corrections to Prior Period Financial Statements (Detail)	Jun. 30, 2015USD ($)
Liabilities
Derivative liabilities, net of current portion	$ 0
Total long-term liabilities	1,146,560
Total liabilities	3,038,449
Stockholders’ deficit
Additional paid-in capital	14,288,150
Accumulated deficit	(14,001,900)
Total stockholders’ deficit	279,406
Scenario, Previously Reported [Member]
Liabilities
Derivative liabilities, net of current portion	6,344,817
Total long-term liabilities	7,491,377
Total liabilities	9,383,266
Stockholders’ deficit
Additional paid-in capital	8,566,193
Accumulated deficit	(14,624,760)
Total stockholders’ deficit	(6,065,411)
Restatement Adjustment [Member]
Liabilities
Derivative liabilities, net of current portion	(6,344,817)
Total long-term liabilities	(6,344,817)
Total liabilities	(6,344,817)
Stockholders’ deficit
Additional paid-in capital	5,721,957
Accumulated deficit	(622,860)
Total stockholders’ deficit	$ 6,344,817

Immaterial Corrections to Pri53

Immaterial Corrections to Prior Period Financial Statements (Statement Of Operations) (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
(Increase)/decrease to fair value of derivative	$ (302,524)	$ 3,546,924
Total other income (expense)	565,844	2,636,785
Net (loss)/income	(772,385)	(1,227,206)
Scenario, Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
(Increase)/decrease to fair value of derivative	(925,384)	2,924,064
Total other income (expense)	(57,016)	2,013,925
Net (loss)/income	(1,395,245)	(1,850,066)
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
(Increase)/decrease to fair value of derivative	(622,860)	(622,860)
Total other income (expense)	(622,860)	(622,860)
Net (loss)/income	$ (622,860)	$ (622,860)

Immaterial Corrections to Pri54

Immaterial Corrections to Prior Period Financial Statements (Statement Of Cash Flow) (Detail) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net (loss)	$ (772,385)	$ (1,227,206)	$ (2,947,526)	$ (8,142,823)
Decrease to fair value of derivative	(302,524)	3,546,924	$ 3,536,294	$ 4,121,693
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net (loss)	(622,860)	(622,860)
Decrease to fair value of derivative	(622,860)	(622,860)
Scenario, Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net (loss)	(1,395,245)	(1,850,066)
Decrease to fair value of derivative	$ (925,384)	$ 2,924,064

Immaterial Corrections to Pri55

Immaterial Corrections to Prior Period Financial Statements - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase (Decrease) in Derivative Liabilities			$ (3,536,294)	$ (4,121,693)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	$ (302,524)	$ 3,546,924	$ 3,536,294	$ 4,121,693
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Adjustments to Additional Paid in Capital, Other		5,721,957
Increase (Decrease) in Derivative Liabilities		6,344,817
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	$ (622,860)	$ (622,860)

Reclassification of Prior Yea56

Reclassification of Prior Year Presentation - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Fair Value Of Derivative Liabilities In Excess Of Proceeds	$ 0	$ (7,541,693)

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event - Convertible Notes Payable [Member]	2 Months Ended
	Dec. 10, 2015USD ($)shares
Business Acquisition, Equity Interests Issued Or Issuable [Line Items]
Debt Conversion Converted Instrument Shares Issued Assitional	255,000
Debt Instrument, Increase, Accrued Interest | $	$ 12,470
Debt Conversion, Converted Instrument, Shares Issued	1,337,347